Current Advancements in 4-Aminoantipyrine-based Scaffolds: Synthesis, Anticancer Potency, and Antimicrobial Efficacy
Insaf Filali, Moncef TounsiAbstract:
Heterocyclic compounds make up the largest and most varied family of organic molecules. Due to expanding synthetic methodologies and a broad spectrum of biological uses, researchers are developing these structures at an unprecedented pace for medicinal chemistry. A prominent representative of this class is 4-aminoantipyrine (4-AAP). As a nitrogen-dense heterocycle featuring a carbonyl group adjacent to a highly reactive amine, 4-AAP serves as an adaptable scaffold characterized by distinct electronic properties and versatile reactivity. Its derivatives are extensively investigated in drug discovery, routinely showing better therapeutic efficacy and fewer toxic side effects than classic pyrazolones. Here, we present a thorough analysis of recent synthetic steps and biological evaluations of 4-AAP derivatives, including Schiff bases, azomethines, and Sand O-alkylated analogs. Particular emphasis is placed on transition metal coordination (including Cu, Ni, Co, Ag, and Mn) and its capacity to modulate drug activity. In oncology, certain structures, particularly dinuclear Copper(II) complexes and Ag(I) chelates, have shown potent cytotoxic activity against MCF-7, HepG2, and HeLa cancer lines. Their IC50 values frequently rival or outperform clinical standard therapeutics like Cisplatin. Regarding antimicrobial activity, incorporating specific pharmacophores like thiazole rings or halogenated aromatics noticeably improves membrane permeability. This results in robust, broad-spectrum efficacy against resistant pathogens such as P. aeruginosa and S. aureus. This study also discusses why chelation is a mechanistic requirement, using Tweedy’s chelation theory to explain how metal complexes achieve greater lipophilicity and bioavailability. Ultimately, by directly linking molecular architecture to anticancer and antibacterial outcomes, this review highlights promising 4-AAP-based lead compounds for future therapeutic development.